2051-1426-1-S1-P144 2051-1426 Poster presentation <p>The impact of cellular senescence and DNA damage on colorectal tumour progression</p> AngellK Helen TosoliniMarie MlecnikBernhard BindeaGabriela FredriksenTessa LafontaineLucie WaldnerMaximilian PagèsFranck Valge-ArcherViia GalonJérôme

Laboratory of Integrative Cancer Immunology, INSERM U872, Paris, France

Université Paris Descartes, Paris, France

Cordeliers Research Centre, Université Pierre et Marie Curie Paris 6, Paris, France

University of Erlangen-Nuremberg, Erlangen, Germany

Immunology, Georges Pompidou European Hospital, Paris, France

MedImmune Ltd, Cambridge, UK

Journal for ImmunoTherapy of Cancer <p>Abstracts of the 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)</p>Carl RubyThis supplement has not been sponsored. The Supplement Editor declares that he has no competing interests.Meeting abstracts<p>Society for Immunotherapy of Cancer 28th Annual Meeting</p>National Harbor, MD, USA8-10 November 2013www.sitcancer.org/20132051-1426 2013 1 Suppl 1 P144 http://www.immunotherapyofcancer.org/content/1/S1/P144 10.1186/2051-1426-1-S1-P144
7112013 2013Angell et al; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We have previously defined the immune contexture as the type, density, location and functional orientation of tumour infiltrating immune cells, associated with patient prognosis in colorectal cancer (CRC). Here we describe potential mechanisms, including the DNA damage response (DDR) and cellular senescence, as contributing factors in shaping this intra-tumoural immune reaction. Cellular senescence, permanent proliferation arrest, is triggered by exogenous or endogenous stress, including telomere shortening, DNA-damage or oncogene activation. We have evaluated the expression of 53BP1, pATM and p16INK4a in a cohort of 205 CRC patients. In addition, telomere length and senescence-associated β-galactosidase have been analysed. A large panel of immune markers, including CD3, CD45RO, CD8 and CD57, were evaluated immunohistochemically. Patients who had increased DDR and senescence correlated with improved prognosis, both disease free and overall survival. Patients with high 53BP1 and pATM had significantly higher numbers of infiltrating immune cells at both the tumour centre and invasive margin. Functional experiments, including a transwell chemotaxis system, have illustrated that immune cells migrate towards soluble factors produced by senescent tumour cells. Our data provide further mechanisms resulting in changes of specific immune cell densities within the tumour, illustrating links between senescence and aspects of the DDR with the control of the anti-tumour immune response, and thus CRC disease progression.